Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of Mubritinib (TAK 165) as an inhibitor of KSHV driven primary effusion lymphoma via disruption of mitochondrial OXPHOS metabolism.
Calderon A, Soldan SS, De Leo A, Deng Z, Frase DM, Anderson EM, Zhang Y, Vladimirova O, Lu F, Leung JC, Murphy ME, Lieberman PM. Calderon A, et al. Among authors: frase dm. Oncotarget. 2020 Nov 17;11(46):4224-4242. doi: 10.18632/oncotarget.27815. eCollection 2020 Nov 17. Oncotarget. 2020. PMID: 33245718 Free PMC article.
Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes.
Soldan SS, Su C, Lamontagne RJ, Grams N, Lu F, Zhang Y, Gesualdi JD, Frase DM, Tolvinski LE, Martin K, Messick TE, Fingerut JT, Koltsova E, Kossenkov A, Lieberman PM. Soldan SS, et al. Among authors: frase dm. PLoS Pathog. 2021 Jun 9;17(6):e1009618. doi: 10.1371/journal.ppat.1009618. eCollection 2021 Jun. PLoS Pathog. 2021. PMID: 34106998 Free PMC article.
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
Konrath KM, Liaw K, Wu Y, Zhu X, Walker SN, Xu Z, Schultheis K, Chokkalingam N, Chawla H, Du J, Tursi NJ, Moore A, Adolf-Bryfogle J, Purwar M, Reuschel EL, Frase D, Sullivan M, Fry B, Maricic I, Andrade VM, Iffland C, Crispin M, Broderick KE, Humeau LMPF, Patel A, Smith TRF, Pallesen J, Weiner DB, Kulp DW. Konrath KM, et al. Cell Rep. 2022 Feb 1;38(5):110318. doi: 10.1016/j.celrep.2022.110318. Epub 2022 Jan 11. Cell Rep. 2022. PMID: 35090597 Free PMC article.
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.
Tebas P, Yang S, Boyer JD, Reuschel EL, Patel A, Christensen-Quick A, Andrade VM, Morrow MP, Kraynyak K, Agnes J, Purwar M, Sylvester A, Pawlicki J, Gillespie E, Maricic I, Zaidi FI, Kim KY, Dia Y, Frase D, Pezzoli P, Schultheis K, Smith TRF, Ramos SJ, McMullan T, Buttigieg K, Carroll MW, Ervin J, Diehl MC, Blackwood E, Mammen MP, Lee J, Dallas MJ, Brown AS, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM. Tebas P, et al. EClinicalMedicine. 2021 Jan;31:100689. doi: 10.1016/j.eclinm.2020.100689. Epub 2020 Dec 24. EClinicalMedicine. 2021. PMID: 33392485 Free PMC article.
DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2.
Parzych EM, Du J, Ali AR, Schultheis K, Frase D, Smith TRF, Cui J, Chokkalingam N, Tursi NJ, Andrade VM, Warner BM, Gary EN, Li Y, Choi J, Eisenhauer J, Maricic I, Kulkarni A, Chu JD, Villafana G, Rosenthal K, Ren K, Francica JR, Wootton SK, Tebas P, Kobasa D, Broderick KE, Boyer JD, Esser MT, Pallesen J, Kulp DW, Patel A, Weiner DB. Parzych EM, et al. Nat Commun. 2022 Oct 6;13(1):5886. doi: 10.1038/s41467-022-33309-6. Nat Commun. 2022. PMID: 36202799 Free PMC article.
Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates.
Walters JN, Schouest B, Patel A, Reuschel EL, Schultheis K, Parzych E, Maricic I, Gary EN, Purwar M, Andrade VM, Doan A, Elwood D, Eblimit Z, Nguyen B, Frase D, Zaidi FI, Kulkarni A, Generotti A, Joseph Kim J, Humeau LM, Ramos SJ, Smith TRF, Weiner DB, Broderick KE. Walters JN, et al. Vaccine. 2022 May 9;40(21):2960-2969. doi: 10.1016/j.vaccine.2022.03.060. Epub 2022 Apr 4. Vaccine. 2022. PMID: 35428500 Free PMC article.
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
Kraynyak KA, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D, Reuschel EL, Purwar M, Christensen-Quick A, Liu N, Andrade VM, Diehl MC, Wani S, Lupicka M, Sylvester A, Morrow MP, Pezzoli P, McMullan T, Kulkarni AJ, Zaidi FI, Frase D, Liaw K, Smith TRF, Ramos SJ, Ervin J, Adams M, Lee J, Dallas M, Shah Brown A, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM, Boyer JD, Mammen MP. Kraynyak KA, et al. J Infect Dis. 2022 Jun 1;225(11):1923-1932. doi: 10.1093/infdis/jiac016. J Infect Dis. 2022. PMID: 35079784 Free PMC article. Clinical Trial.
Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge.
Gary EN, Tursi NJ, Warner BM, Cuismano G, Connors J, Parzych EM, Griffin BD, Bell MR, Ali AR, Frase D, Hojecki CE, Canziani GA, Chaiken I, Kannan T, Moffat E, Embury-Hyatt C, Wooton SK, Kossenkov A, Patel A, Kobasa D, Kutzler MA, Haddad EK, Weiner DB. Gary EN, et al. Front Immunol. 2023 Mar 14;14:1138609. doi: 10.3389/fimmu.2023.1138609. eCollection 2023. Front Immunol. 2023. PMID: 36999023 Free PMC article.
11 results